Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

@article{Black2007OnceyearlyZA,
  title={Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis},
  author={Dennis M Black and Pierre Dominique Delmas and Richard Eastell and Ian R. Reid and Steven Boonen and Jane A. Cauley and Felicia Cosman and Peter L. Lakatos and Ping Chung Leung and Zulema Man and Carlos A. Mautalen and Peter Mesenbrink and Huilin Hu and John Caminis and Karen Tong and Theresa Rosario-Jansen and Joel S. Krasnow and Trisha F. Hue and Deborah E Sellmeyer and Erik F Eriksen and Steven R. Cummings},
  journal={The New England Journal of Medicine},
  year={2007},
  volume={356},
  pages={1809-1822}
}
Background A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period. Methods In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at… Expand
Zoledronic acid treatment of osteoporosis: effects in men.
TLDR
The data suggest that 4 mg of intravenously administered zoledronic acid is an effective treatment for increasing BMD in a "real-world" population of men with osteoporosis and the prolonged suppression of urinary NTx after zoledronics acid infusion raises the question of whether this treatment could be given less frequently than every year. Expand
Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis
TLDR
Treatment with ZOL 5 mg maintained BTMs in the premenopausal range and prevented bone loss in women previously treated with ODN. Expand
Single annual injectable treatment for postmenopausal osteoporosis
TLDR
Yearly zoledronic acid presents a new option for the treatment of postmenopausal osteoporosis, with the perspective of improving the long-term persistence of therapy because of its once-a-year regimen. Expand
The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis
TLDR
Once-yearly zoledronic acid treatment showed bone protection effects by reducing the risk of vertebral fracture and increasing BMD in Chinese women with postmenopausal osteoporosis. Expand
Treatment of osteoporosis with annual iv zoledronic acid: effects on hip fracture
  • R. Chapurlat
  • Medicine
  • Therapeutics and clinical risk management
  • 2009
TLDR
Yearly zoledronic acid reduces the risk of hip fracture, both in postmenopausal osteoporotic women with and without prevalent vertebral fracture and in men and women with a recent first hip fracture. Expand
Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial.
TLDR
Annual administration of doses of iv zoledronate lower than 5 mg produces substantial antiresorptive effects and trials assessing the antifracture efficacy of low doses of zoledronsate are justified. Expand
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
TLDR
In postmenopausal women with osteoporosis previously treated with oral bisphosphonates, denosumab was associated with greater BMD increases at all measured skeletal sites and greater inhibition of bone remodeling compared with ZOL. Expand
Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density
TLDR
Zoledronic acid demonstrated significantly greater decreases in bone turnover markers than did raloxifene in postmenopausal women with low bone mass. Expand
Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment.
TLDR
Premenopausal women receiving chemotherapy for BC sustained significant bone loss during the first year of chemotherapy, without recovery during the second year, and ZA effectively prevented bone loss in this patient population. Expand
Treatment of postmenopausal osteoporosis, patient perspectives – focus on once yearly zoledronic acid
TLDR
ZOL is of proven efficacy, with hip fracture reduction and morphometric vertebral fracture reduction over 3 years in the HORIZON PFT trial, and it has demonstrated a good side-effect profile with postinfusion flu-like symptoms being the most common. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 42 REFERENCES
Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
TLDR
Zoledronic acid infusions given at intervals of up to one year produce effects on bone turnover and bone density as great as those achieved with daily oral dosing with bisphosphonates with proven efficacy against fractures, suggesting that an annual infusion of zoledronic Acid might be an effective treatment for postmenopausal osteoporosis. Expand
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study
TLDR
Oral ibandronate, given daily or with a between-dose interval of >2 months, normalizes the rate of bone turnover, provides significant increases in BMD and a marked reduction in the incidence of vertebral fractures, and has potential to become an important alternative to currently licensed bisphosphonates in postmenopausal osteoporosis. Expand
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.
TLDR
Patients receiving 70 mg OW alendronate had greater gains in B MD, were more likely to maintain or gain BMD, and had greater reductions in bone turnover markers than patients receiving 35 mg OW risedronate after 24 months, with no differences in upper gastrointestinal tolerability. Expand
Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate Versus Risedronate Over Two Years
TLDR
A 1-yr extension of the Fosamax Actonel Comparison Trial was completed to compare changes in bone mineral density, bone turnover, and upper gastrointestinal tolerability over 2 yr of treatment with alendronate, which produced greater increases from baseline in BMD at 24 months. Expand
Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
TLDR
Risedronate 5 mg provides effective and well-tolerated therapy for severe postmenopausal osteoporosis, reducing the incidence of vertebral fractures and improving bone density in women with established disease. Expand
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
TLDR
The data suggest that risedronate therapy is effective and well tolerated in the treatment of women with established postmenopausal osteoporosis. Expand
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
TLDR
Once-monthly oral ibandronate is at least as effective and well tolerated as daily treatment and may be more convenient for patients and improve therapeutic adherence, thereby optimising outcomes. Expand
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
TLDR
Among women with low bone mass and existing vertebral fractures, alendronate is well tolerated and substantially reduces the frequency of morphometric and clinical vertebra fractures, as well as other clinical fractures. Expand
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
TLDR
Salmon calcitonin nasal spray at a dose of 200 IU daily significantly reduces the risk of new vertebral fractures in postmenopausal women with osteoporosis. Expand
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis
TLDR
There was no evidence from this study that combining PTH with alendronate is more effective than giving either agent by itself, and the goal was to learn whether antiresorptive treatment is necessary to maintain the gain in bone mineral density achieved after a year of PTH (1-84). Expand
...
1
2
3
4
5
...